AMGN Amgen Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:15
Jul 05
Jul 05
Undervalued counter-cyclical stocks compound through crises.
A curated group of counter-cyclical stocks that rose during the 2008 crisis and continued delivering high returns now trade at reasonable valuations: AutoZone (car repair proxy, 17% post-crisis annual return), AMGEN (healthcare, 14x earnings), AJ Gallagher (insurance), Pulte Group (homebuilder at 12x, 50% discount to market), Netflix (near-utility at 23x, subscribers sticky), Waste Management (essential waste services), and Darden Restaurants (quality-value dining). These offer crisis protection plus strong compounding, currently overlooked.
MED
19:04
Jun 29
Jun 29
A clinical trial used to approve Amgen's pill Tavneos was retracted from the New England Journal of Medicine, putting the drug's continued sales at risk.
12:48
Jun 26
Jun 26
European Medicines Agency recommends withdrawal of CSL's drug Tavneos over allegedly incorrect and misleading data, adding pressure to US manufacturer Amgen.
09:46
Jun 25
Jun 25
Amgen paid 3.7 billion dollars for a small drugmaker in 2022 and is now contesting an FDA proposal to withdraw the drug due to manipulated research.
03:40
Jun 17
Jun 17
The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.
LOW
01:44
Jun 13
Jun 13
The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.
LOW
21:18
Jun 11
Jun 11
Amgen has engaged an independent academic organization to reevaluate data for a rare disease drug that US regulators are trying to pull from the market.
20:40
Jun 05
Jun 05
The New England Journal of Medicine is investigating allegations of research misconduct in a key study used to approve Amgen's drug Tavneos.
17:47
Jun 03
Jun 03
Healthcare AI adoption benefits AbbVie, Amgen.
Healthcare and biotech companies using AI to improve drug discovery and medical field will see significant gains. Specifically, AbbVie and Amgen are already held in her portfolio and present attractive opportunities as AI adoption accelerates in the sector.
MED
12:56
May 08
May 08
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.
HIGH
00:04
Apr 26
Apr 26
Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27, 2026, but
HIGH
About AMGN Analyst Coverage
Buzzberg tracks AMGN (Amgen Inc.) across 6 sources. 2 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (18%). 11 total trade ideas tracked. Latest voices: Alejandro Estebaranz, Bloomberg, seedy19tron.